Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
A system prompt cleanup at the AI startup led to measurable speed gains, better instruction-following, and significant cost savings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback